Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma

NCT05955508 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05955508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05955508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2024
Completion date
January 25, 2033
Enrollment
40 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

smoldering multiple myeloma (smm)